The future of cannabis is in rare cannabinoids such as CBG, CBN, THCV, THCA, and more, said Dennis O’Neill, president of BioMedican, a biotech company that has developed a unique patented method of producing pharmaceutical-grade cannabinoids.  “These rare cannabinoids offer specific health benefits that are better than CBD,” O’Neill said.

The future of cannabis is in rare cannabinoids such as CBG, CBN, THCV, THCA, and more, said Dennis O’Neill, president of BioMedican, a biotech company that has developed a unique patented method of producing pharmaceutical-grade cannabinoids. “These rare cannabinoids offer specific health benefits that are better than CBD,” O’Neill said.

The future of cannabis is in rare cannabinoids such as CBG, CBN, THCV, THCA, and more, said Dennis O’Neill, president of BioMedican, a biotech company that has developed a unique patented method of producing pharmaceutical-grade cannabinoids.&nbsp; “These rare cannabinoids offer specific health benefits that are better than CBD,” O’Neill said.

The Future of Cannabis Is In Rare Cannabinoids

Best-selling author and entrepreneur Paxton Quigley speaks with the changemakers of the cannabis culture through the eyes of its innovators and influencers who are knee deep in this dynamic space.

Share The Future of Cannabis Is In Rare Cannabinoids

Sign up to save your podcasts

The Future of Cannabis Is In Rare Cannabinoids

The Future of Cannabis Is In Rare Cannabinoids